Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 29 peer-reviewed journal articles Updated
Cardio-Oncology · Anthracycline-Induced Cardiomyopathy

Protecting and Treating Your Heart During Therapy

At a Glance

Heart problems caused by anthracycline chemotherapy may be prevented or treated with individualized care, such as dexrazoxane, selected heart medicines, close monitoring, and chemotherapy dose changes or pauses when needed.

Protecting your heart while effectively treating cancer is a collaborative effort between you, your oncologist, and your cardio-oncologist. If heart stress is detected, or if you are at high risk, there are several strategies and treatments available to help you complete your therapy safely [1][2].

Specialized Chemotherapy Formulations

For selected patients, doctors may use specialized ways to deliver chemotherapy that alter how the drug interacts with the heart [3].

  • Dexrazoxane: This drug is FDA-approved specifically to prevent heart damage from certain anthracyclines (like doxorubicin) in specific clinical settings, typically for patients who have already received a high cumulative dose and need continued treatment [4]. It works by interacting with the TOP2B enzyme and iron within the heart cells [5][6]. Eligibility, timing, and its potential effects on the cancer regimen must be carefully decided by your oncology team [7][8].
  • Liposomal Anthracyclines: These are alternative formulations where the chemotherapy is encased inside a tiny fat bubble (liposome) [4]. In some cancers, this altered distribution reduces the drug’s direct exposure to the heart muscle [8]. However, they are not a universal substitute, they do not completely eliminate heart risk, and the choice to use them depends heavily on the specific type of cancer being treated.

Preventive Heart Medications

For certain high-risk patients, the care team may discuss using common heart medications proactively during treatment, though the evidence for this “primary prevention” is mixed and often shows modest benefits [9].

  • ACE Inhibitors and Beta-Blockers: Medications like lisinopril or carvedilol may be considered selectively to help support the heart muscle [10][11]. Because these drugs can lower blood pressure or heart rate, they require careful monitoring, especially if you are dehydrated or experiencing other chemotherapy side effects [12][13].
  • Statins: While primarily used for lowering cholesterol, some research suggests they might offer minor heart protection, but they are generally prescribed based on standard cardiovascular guidelines [14][15].

Guideline-Directed Heart Failure Therapy

If your heart function (LVEF) drops significantly or you develop symptoms of heart failure, your doctors will utilize individualized, guideline-directed medical therapy (GDMT) designed for Heart Failure with Reduced Ejection Fraction (HFrEF) [16][17]. This typically involves a combination of:

  1. ACE Inhibitors / ARBs or ARNI: Medications (including sacubitril/valsartan, an ARNI) that help relax blood vessels and reduce stress on the heart [18][19].
  2. Beta-Blockers: To help slow the heart rate and reduce workload [20].
  3. MRAs (Mineralocorticoid Receptor Antagonists): Medications like spironolactone [21][22].
  4. SGLT2 Inhibitors: Originally diabetes drugs, now widely used to protect the heart and help manage fluid [17][23].

Important Safety Note: You should never start or stop these medications on your own. They require strict medical monitoring of your blood pressure, kidney function, and electrolytes (like potassium).

Making Decisions About Your Treatment

An abnormal heart test result is a signal for a multidisciplinary conversation [24]. Your medical team will weigh the oncologic benefit against the cardiac risk [1][25].

Possible steps include:

  • Dose Modification: Lowering the dose to a level your heart can better tolerate [1].
  • Treatment Pause: Temporarily holding the chemotherapy while you start heart-protective medications, then “rechallenging” once your heart function stabilizes [26][1].
  • Switching Drugs: Moving to a different chemotherapy if an effective alternative exists [27].

When heart changes are caught early and treated promptly, many patients experience improvement in their heart function, allowing them to balance cancer care with long-term cardiac health [28][29].

Common questions in this guide

Could dexrazoxane help prevent heart damage from my anthracycline?
Dexrazoxane is approved for preventing heart damage from certain anthracycline drugs, such as doxorubicin, in specific clinical situations. It is often considered when a person has received a high cumulative dose and still needs treatment, but the oncology team must decide whether and when it fits the cancer plan.
Would a liposomal anthracycline lower my risk of heart problems?
Liposomal anthracyclines package the drug in a tiny fat-based carrier that can reduce direct exposure of the heart in some cancers. They do not remove heart risk and are not a universal substitute, so the choice depends on the cancer and available treatment options.
What heart medicines are used if anthracycline treatment affects heart function?
If heart function falls substantially or heart-failure symptoms develop, clinicians may use medicines such as an ACE inhibitor, angiotensin receptor blocker, sacubitril/valsartan, beta-blocker, spironolactone, or an SGLT2 inhibitor. These medicines require monitoring of blood pressure, kidney function, and potassium, and should not be started or stopped without the treating team.
Will I have to stop chemotherapy if my heart tests become abnormal?
Not necessarily. The oncology and heart teams may lower the dose, pause treatment while heart medicines take effect, restart it after heart function stabilizes, or switch to another drug if an effective option exists; the decision balances cancer benefit with cardiac risk.
Can heart medicines prevent anthracycline-related heart damage before it starts?
Some high-risk patients may be offered medicines such as ACE inhibitors or beta-blockers during cancer treatment, but studies show mixed and usually modest preventive benefits. These drugs can lower blood pressure or heart rate, so the team must decide whether they are appropriate and monitor you closely, especially if chemotherapy causes dehydration.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my cumulative dose and health history, do I qualify for heart-protective drugs like dexrazoxane?
  2. 2.Is a liposomal version of my chemotherapy an option to help reduce direct exposure to my heart cells?
  3. 3.If my heart tests show a change, will you start me on 'foundational' heart medications like ACE inhibitors or beta-blockers?
  4. 4.If we need to adjust my treatment, what are the chances of restarting the chemotherapy once my heart function stabilizes?
  5. 5.Are there specific blood pressure or heart rate targets we should aim for to keep my heart in its best possible shape during treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (29)
  1. 1

    Role of Myocardial Strain Imaging in Cancer Therapy-Related Cardiac Dysfunction.

    Chaganti BT, Negishi K, Okajima K

    Current cardiology reports 2022; (24(6)):739-748 doi:10.1007/s11886-022-01692-7.

    PMID: 35522421
  2. 2

    Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology.

    Kostakou PM, Kouris NT, Kostopoulos VS, et al.

    Heart failure reviews 2019; (24(1)):91-100 doi:10.1007/s10741-018-9731-y.

    PMID: 30073443
  3. 3

    Chemotherapy-induced cardiotoxicity in children.

    Bansal N, Amdani S, Lipshultz ER, Lipshultz SE

    Expert opinion on drug metabolism & toxicology 2017; (13(8)):817-832 doi:10.1080/17425255.2017.1351547.

    PMID: 28679288
  4. 4

    Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.

    Henriksen PA

    Heart (British Cardiac Society) 2018; (104(12)):971-977 doi:10.1136/heartjnl-2017-312103.

    PMID: 29217634
  5. 5

    Association of early dexrazoxane with reduced cardiotoxicity risk in sarcoma patients treated with anthracycline chemotherapy.

    Jang KH, Wallins JS, Lin IH, et al.

    The oncologist 2025; (30(12)) doi:10.1093/oncolo/oyaf370.

    PMID: 41206057
  6. 6

    Cardiovascular disease in adult survivors of childhood cancer.

    Lipshultz SE, Franco VI, Miller TL, et al.

    Annual review of medicine 2015; (66()):161-76 doi:10.1146/annurev-med-070213-054849.

    PMID: 25587648
  7. 7

    Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.

    de Baat EC, van Dalen EC, Mulder RL, et al.

    The Lancet. Child & adolescent health 2022; (6(12)):885-894 doi:10.1016/S2352-4642(22)00239-5.

    PMID: 36174614
  8. 8

    Review on cardioprotective strategies in the setting of chemotherapy-induced cardiotoxicity.

    Dao V, Amin S, Kammaripalle T, Manning K

    Cardio-oncology (London, England) 2026; (12(1)).

    PMID: 41975552
  9. 9

    Renin-angiotensin System Antagonists and Beta-blockers in Prevention of Anthracycline Cardiotoxicity: a Systematic Review and Meta-analysis.

    Avila MS, Siqueira SRR, Waldeck L, et al.

    Arquivos brasileiros de cardiologia 2023; (120(5)):e20220298 doi:10.36660/abc.20220298.

    PMID: 37255127
  10. 10

    Prevention of anthracycline and trastuzumab-induced decline in left ventricular ejection fraction with angiotensin-converting enzyme inhibitors or angiotensin receptor blocker: a narrative systematic review of randomised controlled trials.

    Lee S, Alsamarrai A, Xiao A, Wang TKM

    Internal medicine journal 2024; (54(8)):1254-1263 doi:10.1111/imj.16437.

    PMID: 38874281
  11. 11

    Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis.

    Abdel-Qadir H, Ong G, Fazelzad R, et al.

    Annals of oncology : official journal of the European Society for Medical Oncology 2017; (28(3)):628-633 doi:10.1093/annonc/mdw671.

    PMID: 28028033
  12. 12

    Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer.

    Guglin M, Krischer J, Tamura R, et al.

    Journal of the American College of Cardiology 2019; (73(22)):2859-2868 doi:10.1016/j.jacc.2019.03.495.

    PMID: 31171092
  13. 13

    Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy ± trastuzumab.

    Gujral DM, Lloyd G, Bhattacharyya S

    Breast (Edinburgh, Scotland) 2018; (37()):64-71 doi:10.1016/j.breast.2017.10.010.

    PMID: 29101824
  14. 14

    Cardio-protective effects of statins in patients undergoing anthracycline-based chemotherapy: An updated meta-analysis of randomized controlled trials.

    Felix N, Nogueira PC, Silva IM, et al.

    European journal of internal medicine 2024; (126()):43-48 doi:10.1016/j.ejim.2024.04.007.

    PMID: 38643042
  15. 15

    Statins for the Primary Prevention of Anthracycline Cardiotoxicity: A Comprehensive Review.

    Bhasin V, Vakilpour A, Scherrer-Crosbie M

    Current oncology reports 2024; (26(10)):1197-1204 doi:10.1007/s11912-024-01579-6.

    PMID: 39002055
  16. 16

    Guidelines for treating heart failure.

    Kittleson MM

    Trends in cardiovascular medicine 2025; (35(3)):141-150 doi:10.1016/j.tcm.2024.10.002.

    PMID: 39442740
  17. 17

    Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice.

    Rosano G, Quek D, Martínez F

    Cardiac failure review 2020; (6()):e31 doi:10.15420/cfr.2020.23.

    PMID: 33294215
  18. 18

    Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan.

    Sokos GG, Raina A

    Vascular health and risk management 2020; (16()):41-51 doi:10.2147/VHRM.S197291.

    PMID: 32021227
  19. 19

    Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy.

    Gregorietti V, Fernandez TL, Costa D, et al.

    Cardio-oncology (London, England) 2020; (6(1)):24 doi:10.1186/s40959-020-00078-4.

    PMID: 33292750
  20. 20

    Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis.

    Burnett H, Earley A, Voors AA, et al.

    Circulation. Heart failure 2017; (10(1)) doi:10.1161/CIRCHEARTFAILURE.116.003529.

    PMID: 28087688
  21. 21

    Patient selection for mineralocorticoid receptor antagonists in heart failure with mildly reduced or preserved ejection fraction.

    Vardeny O, Houle H

    Pharmacotherapy 2023; (43(6)):563-569 doi:10.1002/phar.2801.

    PMID: 37021777
  22. 22

    Pharmacological prevention in cardio-oncology: from bench-to-bedside.

    Avagimyan AA, Pogosova N, Fogacci F, et al.

    Heart failure reviews 2025; (31(1)):7 doi:10.1007/s10741-025-10575-2.

    PMID: 41326864
  23. 23

    Use of EMPAgliflozin in the prevention of CARDiotoxicity: the EMPACARD - PILOT trial.

    Daniele AJ, Gregorietti V, Costa D, López-Fernández T

    Cardio-oncology (London, England) 2024; (10(1)):58 doi:10.1186/s40959-024-00260-y.

    PMID: 39237985
  24. 24

    Features of trastuzumab-related cardiac dysfunction: deformation analysis outside left ventricular global longitudinal strain.

    Nhat GM, Hai NH, Duc VT, et al.

    Frontiers in cardiovascular medicine 2024; (11()):1291180 doi:10.3389/fcvm.2024.1291180.

    PMID: 38312233
  25. 25

    Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper.

    Neuendorff NR, Loh KP, Mims AS, et al.

    Blood advances 2020; (4(4)):762-775 doi:10.1182/bloodadvances.2019000955.

    PMID: 32097461
  26. 26

    Late cardiotoxicity related to HER2-targeted cancer therapy.

    Senechal I, Andres MS, Tong J, et al.

    Cardio-oncology (London, England) 2024; (10(1)):14 doi:10.1186/s40959-024-00215-3.

    PMID: 38454509
  27. 27

    Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial.

    Xue K, Gu JJ, Zhang Q, et al.

    Oncotarget 2016; (7(22)):32519-31 doi:10.18632/oncotarget.8685.

    PMID: 27081036
  28. 28

    Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.

    Cardinale D, Colombo A, Bacchiani G, et al.

    Circulation 2015; (131(22)):1981-8 doi:10.1161/CIRCULATIONAHA.114.013777.

    PMID: 25948538
  29. 29

    Cardiotoxicity of Anthracyclines.

    Cardinale D, Iacopo F, Cipolla CM

    Frontiers in cardiovascular medicine 2020; (7()):26 doi:10.3389/fcvm.2020.00026.

    PMID: 32258060

This page explains ways clinicians may prevent and treat anthracycline-related heart problems for informational purposes only and does not constitute medical advice. Your oncology and cardio-oncology teams must tailor medication and chemotherapy decisions to your health.

Get notified when new evidence is published on Cardiomyopathy due to anthracyclines.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.